Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00552240 · ClinicalTrials.gov registry record · Phase 4
Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)
A Phase 4 study of HIV Infections, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 154
- Enrollment target
- 19
- Study locations
NCT00552240 is a Phase 4 study of HIV Infections that has completed, run by Boehringer Ingelheim. The registered enrollment target is 154 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (65% lower). The trial reports 19 study locations across 11 states.
The verdict
NCT00552240, a Phase 4 study of HIV Infections, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 154 participants
- Enrollment target
- 19
- Study locations
Study Summary
The aim of this clinical trial is to compare the efficacy and safety of ritonavir (RTV)-boosted atazanavir with nevirapine, each on a background of emtricitabine and tenofovir disoproxil fumarate (DF).
Conditions Studied
Interventions
- DRUG tenofovir DF 300 mg QD
- DRUG emtricitabine 200 mg QD
- DRUG Nevirapine 200 mg BID
Study Locations (19)
Texas
- 1100.1512.30 Boehringer Ingelheim Investigational Site - Dallas
- 1100.1512.19 Boehringer Ingelheim Investigational Site - Fort Worth
- 1100.1512.16 Boehringer Ingelheim Investigational Site - Houston
- 1100.1512.24 Boehringer Ingelheim Investigational Site - Houston
Florida
- 1100.1512.17 Boehringer Ingelheim Investigational Site - Fort Lauderdale
- 1100.1512.14 Boehringer Ingelheim Investigational Site - Orlando
- 1100.1512.23 Boehringer Ingelheim Investigational Site - Vero Beach
New Jersey
- 1100.1512.11 Boehringer Ingelheim Investigational Site - Neptune City
- 1100.1512.25 Boehringer Ingelheim Investigational Site - Newark
- 1100.1512.18 Boehringer Ingelheim Investigational Site - Somers Point
California
- 1100.1512.28 Boehringer Ingelheim Investigational Site - Beverly Hills
- 1100.1512.20 Boehringer Ingelheim Investigational Site - Los Angeles
Colorado
- 1100.1512.15 Boehringer Ingelheim Investigational Site - Denver
District of Columbia
- 1100.1512.26 Boehringer Ingelheim Investigational Site - Washington D.C.
Illinois
- 1100.1512.29 Boehringer Ingelheim Investigational Site - Maywood
North Carolina
- 1100.1512.22 Boehringer Ingelheim Investigational Site - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2007-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00552240
The ClinicalTrials.gov registry entry for NCT00552240 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (65% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which tenofovir DF 300 mg QD is the first listed.
NCT00552240 reports 19 study locations spanning 11 distinct geographic areas - top geographies include Texas, Florida, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00552240 about?
NCT00552240 is a clinical study titled "Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)". The aim of this clinical trial is to compare the efficacy and safety of ritonavir (RTV)-boosted atazanavir with nevirapine, each on a background of emtricitabine and tenofovir disoproxil fumarate (DF).
What is the current status of trial NCT00552240?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 154 participants. The study started on 2007-09.
What conditions does trial NCT00552240 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00552240?
The interventions under investigation include: tenofovir DF 300 mg QD (DRUG), emtricitabine 200 mg QD (DRUG), Nevirapine 200 mg BID (DRUG).
Who is sponsoring clinical trial NCT00552240?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00552240 being conducted?
This trial has 19 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accelerated ART Initiation for PWHIV Who Are Out of Care
RECRUITING · Phase 4
-
Vaccine Immunity and Inflammation in the Aging Person Living With HIV
RECRUITING · Phase 4
-
PrEP Intervention for People Who Inject Substances and Use Methamphetamine
RECRUITING · Phase 4
-
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
COMPLETED · Phase 4
-
"The Once A Day Protease Inhibitor Regimens"
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.